Arthritis Therapy Acceleration Programme

If new treatments for the key therapeutic areas currently underpinning the A-TAP of the Immune Mediated Inflammatory Diseases (IMIDs) of Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Sjögren’s  Syndrome (SS) and Spondyloarthropathy (SpA) are to emerge, then a radical new approach which moves the field from an organ-based approach to a process-driven approach is urgently needed.

The A-TAP will bring an innovative new approach to translational inflammation research, accelerating the assessment of novel therapies in the clinic by using pathology based outcome measures in basket trials in Immune Mediated Inflammatory Diseases to determine therapeutic utility and aid tissue based biomarker discovery.   

NHS Partners